AstraZeneca completes acquisition of Takeda’s respiratory business

AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

FTC settles Hikma Roxane competition concerns

6 May 2016 The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.

Big Pharma

Genevant signs $600m liver fibrosis deal with Takeda

18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

FTC settles Hikma Roxane competition concerns

Big Pharma

Genevant signs $600m liver fibrosis deal with Takeda

18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

FTC settles Hikma Roxane competition concerns

Big Pharma

Genevant signs $600m liver fibrosis deal with Takeda

18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.